|
1
|
Druker BJ, Tamura S, Buchdunger E, Ohno S,
Segal GM, Fanning S, Zimmermann J and Lydon NB: Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth of
Bcr-Abl positive cells. Nat Med. 2:561–566. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deininger MW, Goldman JM and Melo JV: The
molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356.
2000.PubMed/NCBI
|
|
3
|
O'Brien SG, Guilhot F, Larson RA, Gathmann
I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
Hughes T, et al: IRIS Investigators: Imatinib compared with
interferon and low-dose cytarabine for newly diagnosed
chronic-phase chronic myeloid leukemia. N Engl J Med. 348:994–1004.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colombat M, Fort MP, Chollet C, Marit G,
Roche C, Preudhomme C, Reiffers J, Praloran V and Mahon FX:
Molecular remission in chronic myeloid leukemia patients with
sustained complete cytogenetic remission after imatinib mesylate
treatment. Haematologica. 91:162–168. 2006.PubMed/NCBI
|
|
5
|
Branford S, Seymour JF, Grigg A, Arthur C,
Rudzki Z, Lynch K and Hughes T: BCR-ABL messenger RNA levels
continue to decline in patients with chronic phase chronic myeloid
leukemia treated with imatinib for more than 5 years and
approximately half of all first-line treated patients have stable
undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer
Res. 13:7080–7085. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Druker BJ, Guilhot F, O'Brien SG, Gathmann
I, Kantarajian H, Gattermann N, Deininger MW, Silver RT, Goldman
JM, Stone RM, et al: IRIS Investigators: Five-year follow-up of
patients receiving imatinib for chronic myeloid leukemia. N Engl J
Med. 355:2408–2417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larson RA, Hochhaus A, Hughes TP, Clark
RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, et
al: Nilotinib vs imatinib in patients with newly diagnosed
Philadelphia chromosome-positive chronic myeloid leukemia in
chronic phase: ENESTnd 3-year follow-up. Leukemia. 26:2197–2203.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kantarjian HM, Shah NP, Cortes JE,
Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW,
Ogura M, et al: Dasatinib or imatinib in newly diagnosed
chronic-phase chronic myeloid leukemia: 2-year follow-up from a
randomized phase 3 trial (DASISION). Blood. 119:1123–1129. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rousselot P, Huguet F, Rea D, Legros L,
Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J,
et al: Imatinib mesylate discontinuation in patients with chronic
myelogenous leukemia in complete molecular remission for more than
2 years. Blood. 109:58–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ross DM, Grigg A, Schwarer A, Arthur C,
Loftus K, Mills AK, et al: The majority of chronic myeloid leukemia
patients who cease imatinib after achieving a sustained complete
molecular response (CMR) remain in CMR, and any relapses occur
early. Blood (ASH Annual Meeting abstracts). 112:402–403. 2008.
|
|
11
|
Mahon FX, Rea D, Guilhot F, Legros L,
Guilhot J, Aton E, Dulucq S, Reiffers J and Rousselot P:
Persistence of complete molecular remission in chronic myeloid
leukemia after imatiib discontinuation: Interim analysis of the
STIM trial. J Clin Oncol. May 20;Supplement. 27:2009.
|
|
12
|
Ross DM and Hughes TP: How I determine if
and when to recommend stopping tyrosine kinase inhibitor treatment
for chronic myeloid leukaemia. Br J Haematol. 166:3–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baccarani M, Cortes J, Pane F,
Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M,
Gratwohl A, Guilhot F, et al: European LeukemiaNet: Chronic myeloid
leukemia: An update of concepts and management recommendations of
European LeukemiaNet. J Clin Oncol. 27:6041–6051. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gabert J, Beillard E, van der Velden VHJ,
Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela
JM, Cavé H, et al: Standardization and quality control studies of
‘real-time’ quantitative reverse transcriptase polymerase chain
reaction of fusion gene transcripts for residual disease detection
in leukemia-A Europe Against Cancer Program. Leukemia.
17:2318–2357. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahon FX, Réa D, Guilhot J, Guilhot F,
Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B,
et al: Intergroupe Français des Leucémies Myéloïdes Chroniques:
Discontinuation of imatinib in patients with chronic myeloid
leukaemia who have maintained complete molecular remission for at
least 2 years: The prospective, multicentre Stop Imatinib (STIM)
trial. Lancet Oncol. 11:1029–1035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY,
Shin S, Kim JA, Kim HS, Cho EH and Kwak JY: Imatinib mesylate
discontinuation in patients with chronic myeloid leukemia who have
received front-line imatinib mesylate therapy and achieved complete
molecular response. Leuk Res. 36:689–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ross DM, Bartley PA, Goyne J, Morley AA,
Seymour JF and Grigg AP: Durable complete molecular remission of
chronic myeloid leukemia following dasatinib cessation, despite
adverse disease features. Haematologica. 96:1720–1722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ross DM, Branford S, Seymour JF, Schwarer
AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, et
al: Patients with chronic myeloid leukemia who maintain a complete
molecular response after stopping imatinib treatment have evidence
of persistent leukemia by DNA PCR. Leukemia. 24:1719–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahon FX, Nicolini FE, Noel MP, Escoffre
M, Charbonnier A, Rea D, Dubruille V, Varet BR, Legros L, Guerci A,
et al: Preliminary report of the STIM2 study: A multicenter stop
imatinib trial for chronic phase chronic myeloid leukemia de novo
patients on imatinib. Blood. 122:6542013.
|
|
20
|
Rousselot P, Charbonnier A, Cony-Makhoul
P, Agape P, Nicolini FE, Varet B, Gradembas M, Etienne G, Rea D,
Roy L, et al: Loss of major molecular kinase inhibitor therapy in
patients with chronic-phase chronic myelogenous leukemia who have
stopped imatinib after durable undetectable disease. J Clin Oncol.
32:424–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
